Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Mengdan Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9347-0770; OpenAlex author ID A5112945019. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Multi-omics analyses inform mechanisms of immunotherapy response in pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1673098↗
  2. M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer. Co-author DOI 10.1111/jcmm.17191↗
  3. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/gs-20-828↗
  4. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  5. Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis. Co-author DOI 10.3892/ol.2019.10444↗
  6. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Co-author DOI 10.1038/s41389-018-0102-2↗
  7. The Role of Stromal Components in Pancreatic Cancer Progression. Co-author DOI 10.2174/1871520616666160404115532↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mengyao Wu · 4 shared papers, 2018–2022 · strength 0.45
  2. Kai Chen · 3 shared papers, 2018–2025 · strength 0.40
  3. Meng Shen · 3 shared papers, 2019–2022 · strength 0.38
  4. Mengyao Wu · 2 shared papers, 2019–2025 · strength 0.35
  5. Min Tao · 3 shared papers, 2018–2020 · strength 0.30
  6. Jinming Cao · 1 shared paper, 2025 · strength 0.25
  7. Dapeng Li · 1 shared paper, 2025 · strength 0.25
  8. Yecheng Li · 1 shared paper, 2025 · strength 0.25
  9. Ge Li · 1 shared paper, 2025 · strength 0.25
  10. Qiaoming Zhi · 2 shared papers, 2018–2019 · strength 0.15
  11. Zhan‐Wen Liang · 1 shared paper, 2022 · strength 0.15
  12. Wei Li · 1 shared paper, 2022 · strength 0.15
  13. Weiming Duan · 1 shared paper, 2022 · strength 0.15
  14. Wei Li · 2 shared papers, 2016–2018 · strength 0.15
  15. Wei Li · 1 shared paper, 2019 · strength 0.10
  16. Yihang Yuan · 1 shared paper, 2019 · strength 0.10
  17. Daoming Li · 1 shared paper, 2019 · strength 0.10
  18. Jian Zhou · 1 shared paper, 2019 · strength 0.10
  19. Wei Li · 1 shared paper, 2019 · strength 0.08
  20. Rui Ren · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.